Fidelity Investments
KYTX icon

Fidelity Investments’s Kyverna Therapeutics KYTX Stock Holding History

Fidelity Investments’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.8K Sell
6,811
-165
-2% -$1.38K ﹤0.01% 4053
2025
Q4 		$65.6K Sell
6,976
-942
-12% -$6.99K ﹤0.01% 3970
2025
Q3 		$47.5K Sell
7,918
-262
-3% -$1.05K ﹤0.01% 3994
2025
Q2 		$25.1K Buy
8,180
+5,787
+242% +$14.3K ﹤0.01% 4203
2025
Q1 		$4.62K Buy
2,393
+784
+49% +$2.32K ﹤0.01% 4729
2024
Q4 		$6.02K Sell
1,609
-5,083
-76% -$24.4K ﹤0.01% 4624
2024
Q3 		$32.7K Buy
+6,692
New +$51.6K ﹤0.01% 3966

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Fidelity Investments's KYTX Position: Q1 2026 in Review

Fidelity Investments reduced its Kyverna Therapeutics (KYTX) stake by 2.4% in Q1 2026, selling an estimated $1.38K and leaving 6,811 shares worth $58.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4053.

Fidelity Investments first reported a position in KYTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $65.6K in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Fidelity Investments held 6,811 shares of Kyverna Therapeutics worth $58.8K as of Q1 2026.
  • Fidelity Investments sold 165 Kyverna Therapeutics shares in Q1 2026, an estimated $1.38K.
  • Kyverna Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4053 holding.
  • Fidelity Investments first reported a position in Kyverna Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Fidelity Investments's Kyverna Therapeutics position peaked at $65.6K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.